Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Epigenetic Therapy
- Non -Small Cell Lung Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 100 years
- Gender
- Both males and females
Description
Objective response rate to Nivolumab preceded by epigenetic priming. Response will be assessed by RECIST 1.1 criteria, baseline scans for this assessment will be the baseline scans done within 4 weeks of enrollment.
Objective response rate to Nivolumab preceded by epigenetic priming. Response will be assessed by RECIST 1.1 criteria, baseline scans for this assessment will be the baseline scans done within 4 weeks of enrollment.
Tracking Information
- NCT #
- NCT01928576
- Collaborators
- Rising Tide Foundation
- Stand Up To Cancer
- Bristol-Myers Squibb
- Celgene
- Syndax Pharmaceuticals, Inc.
- Rhone-Poulenc Rorer
- Investigators
- Principal Investigator: Julie Brahmer, MD Johns Hopkins University
Get Well Soon